Market capitalization | $1.07b |
Enterprise Value | $747.42m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.34 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-93.10m |
Free cash flow (TTM) Free cash flow | $-63.92m |
Cash position | $320.56m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
5 Analysts have issued a Imara Inc forecast:
5 Analysts have issued a Imara Inc forecast:
Mar '24 |
+/-
%
|
||
Net profit | -23 -23 |
-
|
|
Depreciation and amortization | 0.08 0.08 |
-
|
|
Share compensation | 4.52 4.52 |
-
|
|
Operating cash flow | -23 -23 |
-
|
|
Investments | 0.02 0.02 |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -23 -23 |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Samuel Kintz |
Employees | 46 |
Founded | 2019 |
Website | www.enliventherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.